What’s New in the Management and Treatment of GN: A look at ANCA and LN

The complement pathway exerts a central role in the pathophysiology of several glomerular diseases. In lupus nephritis (LN), the complement pathway has been studied for its pathogenic role, its potential as a disease biomarker, and as a therapeutic target. This webinar will briefly approach these aspects and the role of complement research to improve outcomes in lupus nephritis. ANCA will also be a focus of this webinar. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are multisystem disorders resulting in irreversible organ damage. Multiple immune participants contribute to the pathogenesis. The loss of self-tolerance results in the production of ANCA. In humans, therapeutic targeting of C5aR has now demonstrated non-inferiority compared to glucocorticoids and has the potential to be a paradigm changing therapy in AAV. The aim is to personalize management in AAV to improve patient and kidney outcomes.